AGENT™
Drug Coated Balloon

Boston Scientific
Advancing science for life™

Alliance DeNovo Clinical Study

The ALLIANCE Registry[1], presented at TCT 2025, is a Japanese prospective, non-randomized, multicenter, all-comers de novo registry of over 1,800 patients including over 1,300 patients treated with AGENT™ DCB.

Alliance All-Comers De Novo Registry Study Design

Prospective, non-randomized, multicenter, all-comers *de novo* registry of **n = 1,817 patients[2], included after successful lesion preparation**

↓

Stand alone or DES + DCB strategy

DCB	Hybrid
n = 1,592 (88.7 %)	n = 202 (11.3 %)

Image guided PCI was performed on 90% of patients (87% with IVUS), with only 1.1% bailout stenting

Primary Endpoint: Target Lesion Failure at 1-year

Primary Endpoint: The trial met its primary endpoint 1-year Target Lesion Failure (TLF) rate of 4.7 % which was significantly lower than the prespecified performance goal of 7.5 % (p < .001).[2]

Primary Endpoint
4.7% TLF rate at 1-year

0.4% TV-MI at 1-year

2.9% Clinically driven TLR at 1-year

The TLF was driven by low clinically-driven Target Lesion Revascularization (TLR) at 2.9% and Target Vessel Myocardial Infarction (TV-MI) at 0.4%

In ALLIANCE, the excellent outcomes in a complex de novo patient population, may represent a model for achieving optimal DCB outcomes with a modern PCI approach. This study is more representative of real-world practice.

1 Data presented at TCT 2025 by Dr. Masato Nakamura. Results include over 1,300 Japanese patients treated with AGENT DCB (73.3 % of the 1,800 PTX DCB patients)
2 Devices used in this study: AGENT 73.3 % / SeQuent Please Neo 26.4 %

CE 0344

The Latest Clinical Data for DCB: Alliance I